Remove Containment Remove Development Remove Drug Delivery Systems Remove Drugs
article thumbnail

Hydrocortisone by Antares Pharma for Adrenal Insufficiency: Likelihood of Approval

Pharmaceutical Technology

Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. According to GlobalData, Phase I drugs for Adrenal Insufficiency have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is a combination of drug and device.

article thumbnail

Leading commercial dose (non-sterile) companies in contract marketing

Pharmaceutical Technology

The information contained within the download document is intended for pharmaceutical manufacturers, wholesalers, retailers and distributors, pharmaceutical executives, medical representatives, business development managers, retail salesmen, sales managers, pharmacy executives, and any other individual involved in pharmaceutical marketing.

Marketing 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CS acquires AxeroVision’s dry eye disease pipeline

Drug Discovery World

CS Pharmaceuticals (CSP) has acquired AxeroVision, a company developing novel therapies for the treatment of dry eye disease (DED) and other ophthalmic inflammatory diseases that address the underlying inflammatory processes. The post CS acquires AxeroVision’s dry eye disease pipeline appeared first on Drug Discovery World (DDW).

article thumbnail

Five key drug discovery deals of summer 2023

Drug Discovery World

Darren Mercer, Chief Executive of CSP, said: “We are thrilled to acquire AxeroVision, and in particular the pipeline product AXR-270 which contains a novel selective glucocorticoid receptor agonist formulated in a cutting-edge drug delivery system that overcomes the issues of poor compliance and inefficient delivery of conventional eye drops.”

Drugs 52
article thumbnail

Unlocking the potential of mucoadhesive drug delivery

Drug Discovery World

Ashley Rein , Global Market Manager for Topical Drug Delivery at Lubrizol Life Science Health (LLS Health), explains how by using mucoadhesive drug delivery, developers can bring novel drugs to market and maximise the efficacy of pre-existing APIs. . This journey is far from straightforward.

article thumbnail

Drugs Companies Clap Back at Congress…Then Get Sued

FDA Law Blog

Koblitz — After years of silence from FDA on whether certain patents could be listed in the Orange Book, some manufacturers of drug and device combination products have had a rude awakening lately.

Drugs 59
article thumbnail

Liposome: A Novel Drug Delivery System

Roots Analysis

The phospholipid bilayers continuously surround the dispersing aqueous media and create a vesicular system in response to mechanical shaking or heating. The hydrophobic portion contains two fatty acid chains with 10-24 carbon atoms, while the hydrophilic part primarily consists of phosphoric acid linked to a water-soluble molecule.